ALK and non-small cell lung carcinoma: Both subtype-1 and subtype-2 highly express HGF and fibroblast growth factor (FGF)7, which supports NSCLC cell survival through inhibiting anaplastic lymphoma kinase (ALK) inhibitors and epidermal growth factor receptor (EGFR) inhibitors.